BVSNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Bioventus Inc.
Financials through Q2 FY2026, quarter ended Jun 27, 2026Last filing: 10-Q on Aug 5, 2026
$13.49+0.19 (+1.43%)
Close on Oct 19, 2026
- Market cap
- $955.61M
- P/E (TTM)
- 17.5
- Dividend yield
- –
Bioventus Inc. revenue by segment
By business segment
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|
| US Segment | $502.10M | $506.81M | $449.86M | $455.25M | – | – | – | 88.4% | -0.9% |
| International Segment | $65.99M | $66.47M | $62.49M | $56.87M | – | – | – | 11.6% | -0.7% |
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|
| Restorative Therapies | – | – | – | – | $121.57M | $88.62M | $103.50M | – | – |
| Surgical Solutions | – | – | – | – | $87.72M | $61.36M | $54.56M | – | – |
| Pain Treatments | – | – | – | – | $221.61M | $171.18M | $182.08M | – | – |
By region
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|
| United States | $502.10M | $506.81M | $449.86M | $455.25M | $387.55M | $293.70M | $305.07M | 88.4% | -0.9% |
| International | $65.99M | $66.47M | $62.49M | $56.87M | $43.35M | $27.46M | $35.07M | 11.6% | -0.7% |
From the segment and revenue-disaggregation notes of Bioventus's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.